TICKERNOMICS Sign up
Last Update: 2024-12-27 15:22:17
BIOMARIN PHARMACEUTICAL INC ( BMRN ) https://www.biomarin.com
67.02USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-31.00%
BMRN
SPY
32.66%
-25.06%
BMRN
SPY
108.59%
-21.70%
BMRN
SPY
302.52%
-25.81%
BMRN
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
13212.79
-241348.33
0.93
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
41.00
0.02
2.44
2281.53
0.00
-471.10
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.02
74.32
0.03
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
5.5344
26.94
7.63
0.33
Other Earnings and Cash Flow Stats:
BIOMARIN PHARMACEUTICAL INC ( BMRN ) Net Income TTM ($MM) is 322.29
BIOMARIN PHARMACEUTICAL INC ( BMRN ) Operating Income TTM ($MM) is 337.03
BIOMARIN PHARMACEUTICAL INC ( BMRN ) Owners' Earnings Annual ($MM) is 0.00
BIOMARIN PHARMACEUTICAL INC ( BMRN ) Current Price to Owners' Earnings ratio is 0.00
BIOMARIN PHARMACEUTICAL INC ( BMRN ) EBITDA TTM ($MM) is 428.60
BIOMARIN PHARMACEUTICAL INC ( BMRN ) EBITDA Margin is 0.03%
Capital Allocation:
BIOMARIN PHARMACEUTICAL INC ( BMRN ) has paid 0.00 dividends per share and bought back -5.974 million shares in the past 12 months
BIOMARIN PHARMACEUTICAL INC ( BMRN ) has increased its debt by 15.023 million USD in the last 12 months
Capital Structure:
BIOMARIN PHARMACEUTICAL INC ( BMRN ) Interest-bearing Debt ($MM) as of last quarter is 1110
BIOMARIN PHARMACEUTICAL INC ( BMRN ) Annual Working Capital Investments ($MM) are -969861
BIOMARIN PHARMACEUTICAL INC ( BMRN ) Book Value ($MM) as of last quarter is 5413
BIOMARIN PHARMACEUTICAL INC ( BMRN ) Debt/Capital as of last quarter is 21%
Other Balance Sheet Stats:
BIOMARIN PHARMACEUTICAL INC ( BMRN ) has 675 million in cash on hand as of last quarter
BIOMARIN PHARMACEUTICAL INC ( BMRN ) has 715 million of liabilities due within 12 months, and long term debt 1088 as of last quarter
BIOMARIN PHARMACEUTICAL INC ( BMRN ) has 197 common shares outstanding as of last quarter
BIOMARIN PHARMACEUTICAL INC ( BMRN ) has 0 million USD of preferred stock value
Academic Scores:
BIOMARIN PHARMACEUTICAL INC ( BMRN ) Altman Z-Score is 220.50 as of last quarter
BIOMARIN PHARMACEUTICAL INC ( BMRN ) Piotroski Score is 6.00 as of last quarter
Corporate Governance:
BIOMARIN PHARMACEUTICAL INC ( BMRN ) largest shareholder is owning shares at 0.00 ($MM) value
Guyer Charles Greg(an insider) Sold 5278 shares of BIOMARIN PHARMACEUTICAL INC ( BMRN ) for the amount of $350323.56 on 2024-11-12
0.89% of BIOMARIN PHARMACEUTICAL INC ( BMRN ) is held by insiders, and 99.99% is held by institutions
BIOMARIN PHARMACEUTICAL INC ( BMRN ) went public on 1999-07-23
Other BIOMARIN PHARMACEUTICAL INC ( BMRN ) financial metrics:
FCF:321318.79
Unlevered Free Cash Flow:0.00
EPS:2.15
Operating Margin:0.02
Gross Profit Margin:74.32
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:7.84
Beta:0.33
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About BIOMARIN PHARMACEUTICAL INC ( BMRN ) :
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A; BMN 331, an AAV5 mediated gene therapy, which is in Phase 1/2 clinical trial for people living with Hereditary Angioedema (HAE); and BMN 255 that is in Phase 1/2 clinical trial for treating primary hyperoxaluria. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc., and Asubio Pharma Co., Ltd. The company was incorporated in 1996 and is headquartered in San Rafael, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.